Galderma Group AG (GDERF)

Market Cap	46.72B +55.6%
Revenue (ttm)	5.24B +18.0%
Net Income	613.00M +165.4%
EPS	2.58 +166.0%
Shares Out	n/a
PE Ratio	76.21
Forward PE	43.44
Dividend	0.18 (0.09%)
Ex-Dividend Date	Apr 25, 2025

Volume	473
Average Volume	1,127
Open	204.40
Previous Close	192.58
Day's Range	191.00 - 204.40
52-Week Range	108.10 - 213.50
Beta	n/a
RSI	54.57
Earnings Date	Mar 5, 2026

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 7,676
• Stock Exchange: OTCMKTS
• Ticker Symbol: GDERF

Financial Performance

In 2025, Galderma Group AG's revenue was $5.24 billion, an increase of 18.04% compared to the previous year's $4.44 billion. Earnings were $613.00 million, an increase of 165.37%.